Skip to main content
. 2021 Oct 22;11:20871. doi: 10.1038/s41598-021-00150-8

Figure 5.

Figure 5

Dual inhibition of CDK4/6 and HSP90 reduces HIF1α in colorectal cancer cells and synergistically inhibits cell viability in HCT116. (A) HCT116 cells were treated with the indicated inhibitors (ganetespib at 0.05 μM and palbociclib at 10 μM) for 6 h under hypoxia (0.5% O2). (B) SW480 cells were treated with the indicated inhibitors (ganetespib at 0.05 μM, onalespib at 0.05 μM, and palbociclib at 10 μM) for 6 h under hypoxia (0.5% O2). (C, D) CDK4/6 inhibitor palbociclib and HSP90 inhibitor ganetespib or onalespib synergistically inhibit the viability of HCT116 cells at 72 h in normoxia and hypoxia (0.5% O2). (E) Sub-G1 analysis by propidium iodide staining and flow cytometry for HCT116 cells treated with the indicated drug combinations (ganetespib at 0.04 μM; palbocilib at 10 μM) for 48 h. (F) Scratch assay in HT29 cells under CoCl2 treatment (50μΜ) to mimic hypoxia for 72 h. (P: palbociclib; G: ganetespib.) Statistical analysis was performed using one-way ANOVA supplemented with Dunnett test. Mean ± SD was shown. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.